Gastric Cancer Treatment Market By Treatment Type (Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy, Radiation Therapy), By End Use (Hospitals, Clinics, Specialized Cancer Treatment Centers, Ambulatory Surgical Centers) By Geography

 

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Gastric Cancer Treatment Market size was valued at USD 9.5 billion in 2021 and is expected to reach USD 25.6 billion by 2028, at a CAGR of 15.3% during the forecast period 2022 to 2028. Sacral nerve stimulation (SNS) is a therapeutic electrical incitement treatment that is utilized to treat long haul entrail control and bladder control side effects through the adjustment of nerves controlling the lower urinary tract and pelvic floor. Gastric Cancer Market is becoming quickly because of expanding occurrence of adenocarcinoma, lymphoma and gastrointestinal stromal tumors over the globe. Significant drivers for the Gastric Cancer Market are treatment progressions, combination therapies, expanding the number of growth treatment focuses, the extensive number of regulatory approvals for metastatic gastric disease and low measurement radiation innovation based devices. Moreover, the introduction of novel treatments for metastatic stomach disease is relied upon to drive the development of the Gastric Cancer market soon. However, the absence of sufficient monetary help from medical coverage strategies and stringent regulatory framewok for approving complex nature of radiation devices are the main considerations that can hamper the stomach malignancy advertise development over the figure time frame. Different factors, like, high cost of therapy and monetarily less accessibility of medications for the treatment of Gastric Cancer may hamper the worldwide high cost of therapy.

Gastric Cancer Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

15.3%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific
Gastric Cancer Treatment Market DRIVERS AND RESTRAINTS

Currently, the products available in the market constitutes of a broad assortment of treatment choices, for example, angiogenesis inhibitors, new chemotherapies and HER2-focused on therapy. The worldwide gastric cancer treatment market is becoming quickly attributable to the high extent of people with gastric cancer and the nearness of a solid medication pipeline. To pick up footing in this market, the sellers are assembling and marketing gastric cancer drugs hat display a high wellbeing and adequacy profile, this causes the merchants to pick up a focused edge over their peers. In February 2018, Imugene, an invulnerable oncology organization declared that its malignancy immunization yields promising outcomes in gastric disease clinical preliminary examinations and in September 2017, The Food and Drug Administration (FDA) approved the immunotherapy drug pembrolizumab (Keytruda®) to be utilized on patients with cutting edge gastric cancer growth.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Gastric Cancer Treatment Market Segmentation

treatment type
  • Chemotherapy
  • Adjuvant Chemotherapy
  • Radiation Therapy
  • Surgery
  • Targeted Therapy
Cancer Type
  • Laryngeal Cancer
  • Lip and Oral Cavity Cancer
  • Nasopharyngeal Cancer
  • Oropharyngeal Cancer
  • Salivary Gland Cancer
  • Others
By End User

Frequently Asked Questions

The gastric cancer treatment market is projected to expand at a CAGR of 15.3% during the forecast period

Abbott Laboratories, AstraZeneca plc, Eli Lilly and Company, Hoffmann-La Roche Ltd, Pfizer, Inc.

North America is the fastest-growing region for gastric cancer treatment market

 

  • Abbott Laboratories, Inc.(U.S)
  • AstraZeneca plc (U.K)
  • Eli Lilly and Company(U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Pfizer, Inc. (U.S.)
  • GlaxoSmithKline plc (UK)
  • Amgen, Inc.(U.S)
  • Celgene corporation (U.S)
  • Novartis AG (Switzerland)